雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

検索

書誌情報 詳細検索 by 医中誌

Japanese

Key points in evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021 Noriyuki Kawami 1 , Katsuhiko Iwakiri 1 1Department of Gastroenterology, Nippon Medical School, Graduate School of Medicine, Tokyo, Japan Keyword: gastroesophageal reflux disease (GERD) , reflux esophagitis , non-erosive reflux disease (NERD) pp.568-575
Published Date 2023/5/25
DOI https://doi.org/10.24479/endo.0000000726
  • Abstract
  • Look Inside
  • Reference

 Vonoprazan is a potassium-competitive acid blocker and a potent acid secretion inhibitor that became available in Japan in 2015. The need to add new data, including the treatment outcomes of vonoprazan, in the gastroesophageal reflux disease (GERD) practice guidelines led to the publication of the third edition of the practice guidelines for GERD in 2021. The important clinical issues addressed in the revision are (i) introduction of treatment algorithms that classify GERD into reflux esophagitis and non-erosive reflux disease, (ii) clarification of treatment algorithms in accordance with the severity of reflux esophagitis, and (iii) positioning of vonoprazan in the treatment of GERD. The present guidelines propose vonoprazan 20mg once daily for 4 weeks as initial treatment and vonoprazan 10mg once daily as maintenance treatment for severe reflux esophagitis. The guidelines recommend vonoprazan or a proton-pump inhibitor (PPI) as the initial treatment for mild reflux esophagitis because PPIs and vonoprazan both achieve esophageal mucosal healing in the initial treatment of mild reflux esophagitis. PPI is recommended and vonoprazan is proposed as maintenance treatment for mild reflux esophagitis because there is currently insufficient information on the safety of long-term vonoprazan therapy.


© tokyo-igakusha.co.jp. All right reserved.

基本情報

電子版ISSN 印刷版ISSN 0915-3217 東京医学社

関連文献

もっと見る

文献を共有